IDEAYA Biosciences, Inc. (IDYA) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 97.9% | -72.8% | -52.0% |
| 2024 | 45.2% | -4671.1% | -3921.1% |
| 2023 | 82.9% | -574.9% | -483.0% |
| 2022 | 95.9% | -122.7% | -115.2% |
| 2021 | 93.8% | -179.9% | -178.1% |
Download Data
Export IDYA earnings history in CSV or JSON format
Free sign-in required to download data
IDEAYA Biosciences, Inc. (IDYA) Earnings Overview
As of February 28, 2026, IDEAYA Biosciences, Inc. (IDYA) reported trailing twelve-month net income of -$114M, reflecting +0.6% year-over-year growth. The company earned $-1.28 per diluted share over the past four quarters, with a net profit margin of -0.5%.
Looking at the long-term picture, IDYA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$12M in fiscal 2017.
IDEAYA Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including RVMD (-$1.13B net income), INCY ($1.29B net income, 0.3% margin), GMAB ($6.57B net income, 0.4% margin), IDYA has comparable earnings metrics. Compare IDYA vs RVMD →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$114M | +58.6% | -$159M | $-1.28 | -52.0% | -72.8% |
| 2024 | -$274M | -143.0% | -$327M | $-3.36 | -3921.1% | -4671.1% |
| 2023 | -$113M | -92.6% | -$134M | $-1.96 | -483.0% | -574.9% |
| 2022 | -$59M | -17.9% | -$63M | $-1.42 | -115.2% | -122.7% |
| 2021 | -$50M | -44.3% | -$50M | $-1.41 | -178.1% | -179.9% |
| 2020 | -$34M | +17.8% | -$35M | $-1.31 | -176.6% | -180.9% |
| 2019 | -$42M | -22.2% | -$44M | $-1.90 | - | - |
| 2018 | -$34M | -189.5% | -$36M | $-2.41 | - | - |
| 2017 | -$12M | - | -$14M | $-0.83 | - | - |
See IDYA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IDYA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare IDYA vs AGIO
See how IDYA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is IDYA growing earnings?
IDYA EPS of $-1.28 reflects slowing growth at +0.6%, below the 5-year CAGR of N/A. TTM net income is $-114M. Expansion rate has moderated.
What are IDYA's profit margins?
IDEAYA Biosciences, Inc. net margin is -0.5%, with operating margin at -0.7%. Below-average margins reflect competitive or cost pressures.
How consistent are IDYA's earnings?
IDYA earnings data spans 2017-2025. The current earnings trend is +0.6% YoY. Historical data enables comparison across business cycles.